Cardiovascular Toxicities of CAR T-cell Therapy

[11] Shaw P(2016)Global manufacturing of CAR T cell therapy Mol Ther Methods Clin Dev 4 4017-56

[12] Berg RA(2015)CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Blood. 125 2868-2544

[13] June CH(2019)Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed/refractory (R/R) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, outreach, and PILOT Blood 134 439-1342

[14] Porter DL(2018)Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 378 45-852

[15] Frey NV(2019)Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 380 2531-847

[16] Grupp SA(2017)Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 377 1331-109

[17] Teachey DT(2020)KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma N Engl J Med 382 839-55

[18] Burstein DS(2020)Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicenter seamless design study Lancet. 396 836-947

[19] Maude S(2017)Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia N Engl J Med 376 97-110

[20] Grupp S(2020)CAR T cell therapy–related cardiovascular outcomes and management JACC: CardioOncology 2 45-46

[11] Shaw P(2016)Global manufacturing of CAR T cell therapy Mol Ther Methods Clin Dev 4 4017-56

[12] Berg RA(2015)CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Blood. 125 2868-2544

[13] June CH(2019)Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed/refractory (R/R) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, outreach, and PILOT Blood 134 439-1342

[14] Porter DL(2018)Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 378 45-852

[15] Frey NV(2019)Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 380 2531-847

[16] Grupp SA(2017)Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 377 1331-109

[17] Teachey DT(2020)KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma N Engl J Med 382 839-55

[18] Burstein DS(2020)Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicenter seamless design study Lancet. 396 836-947

[19] Maude S(2017)Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia N Engl J Med 376 97-110

[20] Grupp S(2020)CAR T cell therapy–related cardiovascular outcomes and management JACC: CardioOncology 2 45-46